Indian drug regulator joins global med device regulators' club
Drug regulator Central Drugs Standard Control Organisation (CDSCO) has joined the International Medical Device Regulators Forum (IMDRF) network as an affiliate member.
Drug regulator Central Drugs Standard Control Organisation (CDSCO) has joined the International Medical Device Regulators Forum (IMDRF) network as an affiliate member.
Vitamin tablets Shelcal, antiacid Pan-D, paracetamol IP 500 mg, Type-2 diabetic drug Glimepiride, hypertension drug Telmisartan and antibiotics Cepodem as well as Clavam were of non-standard quality.
The ministry wants the policy to simplify the licensing system to avoid duplication of efforts and ensure better coordination among different regulatory authorities
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
A list out 51 medical problems including several metabolic disorders has been brought under the duty exempted category for import for personal use.
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.
The seizure is the biggest haul at any airport in India.